CHRONIC ATYPICAL NEUROLEPTIC TREATMENT IN NORMALLY DEVELOPING MACACA NEMESTRINA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。非典型抗精神病药物被广泛应用于患有严重精神病理的儿童和青少年。这些药物对正常生长发育的影响尚不清楚。这个为期5年的项目从13-20个月大开始用利培酮、喹硫平或安慰剂治疗正常发育的非人灵长类动物（猕猴nemestrina），然后是4个月的药物后期。12名男性将接受低剂量的利培酮或喹硫平4个月，然后切换到高剂量4个月。24名男性将被分配到安慰剂组。动物在药物或安慰剂治疗之前、期间和之后接受测试：(1)社交、情感、探索、学习和记忆、运动技能和感知行为；(2)健康、躯体生长、骨矿化和激素功能的物理评估。研究设计允许组间和个体内比较，以检查药物组差异以及剂量效应。由于nemestrina猴表现出与人类相当的心理和躯体发育，该项目将确定可能受到这些药物长期治疗影响的人类发育方面。每年将对12-20只猴子进行研究，目前有20只正在接受测试。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Atypical neuroleptic drugs are being used frequently in children and adolescents with severe psychopathology. The effects of these agents on normal growth and development are unknown. This 5-year project treats normally developing non-human primates (macaque nemestrina) with risperidone, quetiapine, or placebo from 13-20 months of age, followed by a 4 month post-drug period. 12 males will receive a low dose of risperidone or quetiapine for 4 months, then switched to a high dose for 4 months. 24 males will be assigned to the placebo condition. Animals are being tested before, during, and after drug or placebo treatment for (1) social, emotional, exploratory, learning and memory, motor skill, and perceptual behavior; and (2) physical assessments of health, somatic growth, bone mineralization, and hormonal function. The study design permits both between-group and within-individual comparisons to examine drug group differences as well as dose effects. Since m. nemestrina monkeys demonstrate psychological and somatic development comparable to humans, this project will identify aspects of human development that are likely to be affected by chronic treatment with these agents. 12-20 monkeys will be studied each year, with 20 currently being tested.